Two main methods have been proposed in relation to bladder ART ... 48% of patients received neoadjuvant or adjuvant radiotherapy and/or chemotherapy. § 24% of patients received postoperative ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by ... Previous trials of neoadjuvant and adjuvant immunotherapy showed clinical benefit in this setting ...

There are about 80,000 new cases of bladder cancer every year in the US alone ... This research has determined that ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

“We are disappointed in the ADJUVANT BR.31 results ... NIAGARA compared Imfinzi plus chemo to chemo alone in muscle-invasive bladder cancer (MIBC) patients scheduled for a cystectomy to ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

“The medical term for preventative chemotherapy is adjuvant chemotherapy.” However, preventative chemotherapy should not be confused with cancer prevention—medical and lifestyle decisions aimed at ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

A multigene signature can be used to guide decisions about adjuvant therapy in patients with triple-negative breast cancer, data suggest.

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study ...

Pertuzumab (Perjeta) treats HER2-positive early breast cancer, usually in combination with trastuzumab and chemotherapy. It’s FDA-approved for neoadjuvant and adjuvant treatment. Neoadjuvant use ...